ERBB2 and neoplasm: Unfortunately, despite recent significant improvements in outcomes due to modern adjuvant therapies, approximately 25% of women with early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) tumor experience disease recurrence [3, 4].